Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acute Spinal Cord Injury (SCI) (2 trials), Spinal Cord Diseases (2 trials), Central Nervous System Diseases, Nervous System Diseases, Trauma, Nervous System, Spinal Cord Injuries (SCI), Wounds and Injuries, Spinal Cord Injuries and 1 more
- Main trialPhase 1
- “This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004. The trial consists of Part A (the dose escalation) and Part B (the PK-confirmation at 2 dose levels from Part A).”In the company’s words, NCT06817577 on ClinicalTrials.gov
Other drugs for Acute Spinal Cord Injury (SCI)
Coming up2
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
- Jul 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Mar 2027 | NG004 in Spinal Cord Injury Patients | |
| Phase 1Recruiting | Jul 2029 | NG004 in Incomplete Spinal Cord Injury Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026